

Supplemental Figure 1: Dasatinib does not enhance BRAFi/MEKi efficacy in therapy naïve setting. **(A)** The therapy naïve PDX model WM4237-1 was implanted s.q. into an NSG mouse. Treatment with vehicle control, dasatinib, BRAFi//MEKi, or dasatinib + BRAFi/MEKi began when tumors were palpable (denoted with black arrow).

Supplemental Figure

A

WM4237-1

